Record Revenue Outlook Could Be A Game Changer For Repligen (RGEN)

What happened: Repligen ($RGEN) reported record Q3 2026 revenue and nine-month revenue but posted net losses for both periods, including a US$41.24 million intangible asset impairment in the quarter. Why it matters: The content frames the impairment as mostly a one off linked to BioLife, with integration execution and cost discipline as the near term catalyst. The key risk cited is that spending and softer biotech funding keep earnings under pressure. Market: -2.4% today ($175.80), +7.0% YTD, 1.9x vol — as of 23:45 UTC Verified: Q3_2026 (Oct 27) EPS $0.53 vs $0.46 est, +14.6% beat; next print ~Jan 26

Repligen ($RGEN) reported record Q3 2026 revenue and nine-month revenue but posted net losses for both periods, including a US$41.24 million intangible asset impairment in the quarter.

The content frames the impairment as mostly a one off linked to BioLife, with integration execution and cost discipline as the near term catalyst. The key risk cited is that spending and softer biotech funding keep earnings under pressure. Market: -2.4% today ($175.80), +7.0% YTD, 1.9x vol — as of 23:45 UTC Verified: Q3_2026 (Oct 27) EPS $0.53 vs $0.46 est, +14.6% beat; next print ~Jan 26